These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

288 related articles for article (PubMed ID: 35599922)

  • 1. Emerging advances in the pharmacologic treatment of nonalcoholic steatohepatitis and related cirrhosis.
    Sinakos E; Liava C; Loomba R
    Ann Gastroenterol; 2022; 35(3):213-225. PubMed ID: 35599922
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pharmacologic therapy for nonalcoholic steatohepatitis focusing on pathophysiology.
    Yoon IC; Eun JR
    Yeungnam Univ J Med; 2019 May; 36(2):67-77. PubMed ID: 31620616
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Emerging and Established Therapeutic Approaches for Nonalcoholic Fatty Liver Disease.
    Brown E; Hydes T; Hamid A; Cuthbertson DJ
    Clin Ther; 2021 Sep; 43(9):1476-1504. PubMed ID: 34446271
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Narrative review of current and emerging pharmacological therapies for nonalcoholic steatohepatitis.
    Satiya J; Snyder HS; Singh SP; Satapathy SK
    Transl Gastroenterol Hepatol; 2021; 6():60. PubMed ID: 34805582
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Promising therapies for treatment of nonalcoholic steatohepatitis.
    Noureddin M; Zhang A; Loomba R
    Expert Opin Emerg Drugs; 2016 Sep; 21(3):343-57. PubMed ID: 27501374
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Current and future therapeutic regimens for nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Younossi ZM; Loomba R; Rinella ME; Bugianesi E; Marchesini G; Neuschwander-Tetri BA; Serfaty L; Negro F; Caldwell SH; Ratziu V; Corey KE; Friedman SL; Abdelmalek MF; Harrison SA; Sanyal AJ; Lavine JE; Mathurin P; Charlton MR; Chalasani NP; Anstee QM; Kowdley KV; George J; Goodman ZD; Lindor K
    Hepatology; 2018 Jul; 68(1):361-371. PubMed ID: 29222911
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical epidemiology and disease burden of nonalcoholic fatty liver disease.
    Perumpail BJ; Khan MA; Yoo ER; Cholankeril G; Kim D; Ahmed A
    World J Gastroenterol; 2017 Dec; 23(47):8263-8276. PubMed ID: 29307986
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment options for nonalcoholic fatty liver disease.
    Lam B; Younossi ZM
    Therap Adv Gastroenterol; 2010 Mar; 3(2):121-37. PubMed ID: 21180596
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Advances in hepatocellular carcinoma: Nonalcoholic steatohepatitis-related hepatocellular carcinoma.
    Khan FZ; Perumpail RB; Wong RJ; Ahmed A
    World J Hepatol; 2015 Aug; 7(18):2155-61. PubMed ID: 26328027
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Molecular Mechanisms of Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH).
    Ota T
    Adv Exp Med Biol; 2021; 1261():223-229. PubMed ID: 33783745
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Current pharmacological therapies for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis.
    Takahashi Y; Sugimoto K; Inui H; Fukusato T
    World J Gastroenterol; 2015 Apr; 21(13):3777-85. PubMed ID: 25852263
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The American lifestyle-induced obesity syndrome diet in male and female rodents recapitulates the clinical and transcriptomic features of nonalcoholic fatty liver disease and nonalcoholic steatohepatitis.
    Harris SE; Poolman TM; Arvaniti A; Cox RD; Gathercole LL; Tomlinson JW
    Am J Physiol Gastrointest Liver Physiol; 2020 Sep; 319(3):G345-G360. PubMed ID: 32755310
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Updates on novel pharmacotherapeutics for the treatment of nonalcoholic steatohepatitis.
    Yang YY; Xie L; Zhang NP; Zhou D; Liu TT; Wu J
    Acta Pharmacol Sin; 2022 May; 43(5):1180-1190. PubMed ID: 35190696
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of Nonalcoholic Fatty Liver Disease.
    Liangpunsakul S; Chalasani N
    Curr Treat Options Gastroenterol; 2003 Dec; 6(6):455-463. PubMed ID: 14585234
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Nonalcoholic Fatty Liver Disease and Non-Alcoholic Steatohepatitis: Current Issues and Future Perspectives in Preclinical and Clinical Research.
    Berardo C; Di Pasqua LG; Cagna M; Richelmi P; Vairetti M; Ferrigno A
    Int J Mol Sci; 2020 Dec; 21(24):. PubMed ID: 33348908
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Challenges and Management of Liver Cirrhosis: Practical Issues in the Therapy of Patients with Cirrhosis due to NAFLD and NASH.
    Traussnigg S; Kienbacher C; Halilbasic E; Rechling C; Kazemi-Shirazi L; Hofer H; Munda P; Trauner M
    Dig Dis; 2015; 33(4):598-607. PubMed ID: 26159280
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pathophysiology of NASH in endocrine diseases.
    Gariani K; Jornayvaz FR
    Endocr Connect; 2021 Feb; 10(2):R52-R65. PubMed ID: 33449917
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Can Nutritional Supplements Benefit Patients With Nonalcoholic Steatohepatitis and Nonalcoholic Fatty Liver Disease?
    Baradeiya AM; Taghlabi KM; Saleh AN; Manikonda S; Salim SS
    Cureus; 2023 Jun; 15(6):e40849. PubMed ID: 37489221
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Nonalcoholic Fatty Liver Disease--The Clinician's Perspective.
    Agrawal S; Duseja A
    Trop Gastroenterol; 2014; 35(4):212-21. PubMed ID: 26349165
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Nonalcoholic fatty liver disease].
    Lemoine M; Serfaty L
    Presse Med; 2012 Feb; 41(2):169-89. PubMed ID: 21723084
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 15.